Effect of Levosimendan on Low Cardiac Output Syndrome After Pericardiectomy.

IF 2.8 3区医学 Q1 Pharmacology, Toxicology and Pharmaceutics Therapeutics and Clinical Risk Management Pub Date : 2024-12-13 eCollection Date: 2024-01-01 DOI:10.2147/TCRM.S496574

Likui Fang, Pengfei Zhu, Guocan Yu, Wang Lv, Jian Hu

{"title":"Effect of Levosimendan on Low Cardiac Output Syndrome After Pericardiectomy.","authors":"Likui Fang, Pengfei Zhu, Guocan Yu, Wang Lv, Jian Hu","doi":"10.2147/TCRM.S496574","DOIUrl":null,"url":null,"abstract":"Background: Low cardiac output syndrome (LCOS) after pericardiectomy is associated with high morbidity and mortality. This study aimed to assess the effect of levosimendan on postoperative LCOS in the patients with constrictive pericarditis.Methods: Patients were retrospectively enrolled, and those receiving the treatment of levosimendan were assigned in the LEVO (+) group, and others were in the LEVO (-) group. Postoperative outcomes including durations of intubation, vasoactive agents using, ICU stay, hospital stay and mortality were compared between the two groups.Results: A total of 32 patients were eligible for analysis, 19 of whom were in the LEVO (+) group, and 13 of whom were in the LEVO (-) group. The LEVO (+) group was associated with shorter postoperative duration of intubation (P < 0.001), vasopressor using (P = 0.006), ICU stay (P = 0.001) and hospital stay (P = 0.042), and less incidence of acute liver or kidney injury (P = 0.046). There were no significant differences in 30-day mortality and 1-year mortality between the LEVO (+) group and the LEVO (-) group. The prevalence of adverse events in the LEVO (+) group was acceptable.Conclusion: Levosimendan could be administered in the patients with constrictive pericarditis developing LCOS after pericardiectomy to enhanced postoperative recovery.","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"20 ","pages":"861-869"},"PeriodicalIF":2.8000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651068/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S496574","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Low cardiac output syndrome (LCOS) after pericardiectomy is associated with high morbidity and mortality. This study aimed to assess the effect of levosimendan on postoperative LCOS in the patients with constrictive pericarditis.

Methods: Patients were retrospectively enrolled, and those receiving the treatment of levosimendan were assigned in the LEVO (+) group, and others were in the LEVO (-) group. Postoperative outcomes including durations of intubation, vasoactive agents using, ICU stay, hospital stay and mortality were compared between the two groups.

Results: A total of 32 patients were eligible for analysis, 19 of whom were in the LEVO (+) group, and 13 of whom were in the LEVO (-) group. The LEVO (+) group was associated with shorter postoperative duration of intubation (P < 0.001), vasopressor using (P = 0.006), ICU stay (P = 0.001) and hospital stay (P = 0.042), and less incidence of acute liver or kidney injury (P = 0.046). There were no significant differences in 30-day mortality and 1-year mortality between the LEVO (+) group and the LEVO (-) group. The prevalence of adverse events in the LEVO (+) group was acceptable.

Conclusion: Levosimendan could be administered in the patients with constrictive pericarditis developing LCOS after pericardiectomy to enhanced postoperative recovery.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

左西孟旦对心包切除术后低心输出量综合征的影响。

背景：心包切除术后低心输出量综合征（LCOS）具有较高的发病率和死亡率。本研究旨在评估左西孟旦对缩窄性心包炎患者术后LCOS的影响。方法：回顾性纳入患者，将接受左西孟旦治疗的患者分为LEVO（+）组，其余患者分为LEVO（-）组。比较两组患者的术后结果，包括插管时间、血管活性药物的使用、ICU住院时间、住院时间和死亡率。结果：共有32例患者符合分析条件，其中LEVO（+）组19例，LEVO（-）组13例。LEVO（+）组术后插管时间（P < 0.001）、血管加压药物使用（P = 0.006）、ICU住院时间（P = 0.001）和住院时间（P = 0.042）较短，急性肝肾损伤发生率较低（P = 0.046）。LEVO（+）组与LEVO（-）组30天死亡率和1年死亡率无显著差异。LEVO（+）组的不良事件发生率是可以接受的。结论：左西孟旦可用于缩窄性心包炎心包切除术后LCOS患者，以促进术后恢复。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-

CiteScore

5.30

自引率

3.60%

发文量

139

审稿时长

16 weeks

期刊介绍： Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.